Shares of Amarin (AMRN -11.8%) and Horizon Pharma (HZNP -17.4%) sank after each received FDA approval of key drugs. Buying the rumor and selling the news? In the case of AMRN's Vascepa, investors are still waiting for New Chemical Entity status to make sure there isn’t a generic competitor. For HZNP, investors may doubt its ability to market its Rayos rheumatoid arthritis treatment.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Mon, 9:13AM)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs